GSK appoints two non-executive directors to its Board
pharmafile | May 3, 2012 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | GSK, Jing Ulrich, Lynn Elsenhans
GlaxoSmithKline has announced that Lynn Elsenhans and Jing Ulrich will join the Board of the Company with effect from 1 July as non-executive directors.
Elsenhans was chair, president and chief executive of Sunoco, a transportation fuel provider in the US from 2009 to 2012. Prior to joining Sunoco as chief executive in 2008, for almost 30 years, Elsenhans worked for Royal Dutch Shell, latterly as executive vice president, Global Manufacturing.
Ulrich (pictured) is currently managing director and chairman of Global Markets, China at J.P. Morgan, serving as an adviser to global institutions across various industries and asset classes. Before joining them in 2005, she held senior positions as a managing director for several financial institutions in the Asia Pacific region.
Commenting on the appointments, Sir Christopher Gent, chairman of GSK, said:
“I am delighted to welcome Lynn and Jing to the Board of GSK. These appointments reflect proactive succession planning to ensure the Board’s membership is continuously refreshed and that it provides the leadership necessary to take GSK’s global business forward.
“Today’s announcement also reflects the Board’s priority of appointing candidates who have deep knowledge of Emerging Markets or experience of running global companies.”
GSK also announced that Sir Deryck Maughan will be joining the Remuneration Committee with effect from 1 July, and Judy Lewent will join the Remuneration Committee from the start of next year. Tom de Swaan and Professor Sir Roy Anderson will join the Nominations Committee on this date also.
Related Content
GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis
GSK’s Exdensur (depemokimab), a twice-yearly biological medicine, has received approval from the UK Medicines and …
Multiple myeloma treatment approved in Japan
GSK’s Blenrep (belantamab mafodotin) combinations have been approved by Japan’s Ministry of Health, Labour and …
US FDA expands Jemperli (dostarlimab-gxly) plus chemotherapy approval to all adult patients with primary advanced or recurrent endometrial cancer as the first and only immuno-oncology-based treatment to show an overall survival benefit
PHILADELPHIA–GSK plc today announced the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab-gxly) in combination …
